Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022

BACKGROUND: In summer 2022, SARS-CoV-2 Omicron BA.5 became dominant in Europe. In vitro studies have shown a large reduction of antibody neutralisation for this variant. AIM: We aimed to investigate differences in protection from previous infection and/or vaccination against infection with Omicron B...

Descripción completa

Detalles Bibliográficos
Autores principales: Andeweg, Stijn P, de Gier, Brechje, Vennema, Harry, van Walle, Ivo, van Maarseveen, Noortje, Kusters, Nina E, de Melker, Hester E, Hahné, Susan JM, van den Hof, Susan, Eggink, Dirk, Knol, Mirjam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936591/
https://www.ncbi.nlm.nih.gov/pubmed/36795499
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2200724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936591/
https://www.ncbi.nlm.nih.gov/pubmed/36795499
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2200724

Ejemplares similares